Skip to Content
  • Another Longevity Target

    Add another potential target to the longevity list: this paper in Cell (open access, actually) provides evidence that the well-known Ras-ERK-ETS pathway is also… Read More
  • Two Types of Risk

    It’s the time for the ASCO meeting again, so everyone who follows oncology drug development will be busy catching up on the news. Bruce Booth has a good o… Read More
  • The Nativis Voyager Appears

    To my surprise, there has apparently been a sighting of the “Natavis Voyager” device in the wild. Nativis, as long-time readers will recall, is the… Read More
  • Aileron and p53

    In the long-running saga of getting a stapled peptide to work as a drug, Aileron Therapeutics was last heard from raising money for their p53 candidate. Now com… Read More
  • PD-1 Charted

    Via AndyBiotech on Twitter, here’s a chart from the ongoing AACR meeting on what sorts of tumors are responding best to the PD-1 antibodies that are creat… Read More
  • Stopped For Efficacy – Again

    Well, just weeks after Merck halted a trial of their anti PD-1 antibody Keytruda (pembrolizumab) due to efficacy, Bristol-Myers Squibb has announced that a tria… Read More
Page 10 of 38« First...89101112...2030...Last »